interleukin 28B genetic polymorphism and hepatitis B virus infection

interleukin(iL)28B genetic polymorphism is significantly associated with the sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-α(PEG-iFN)plus ribavirin and with spontaneous hepatitis C virus clearance.However,a consensus on the relationship be...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 34; pp. 12026 - 12030
Main Author Takahashi, Toru
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 14.09.2014
Subjects
28B
Animals
Antiviral Agents - therapeutic use
Biomarkers - blood
Drug Therapy, Combination
Genotype
Hepatitis
Hepatitis B e Antigens - blood
Hepatitis B Surface Antigens - blood
Hepatitis B virus - drug effects
Hepatitis B virus - immunology
Hepatitis B virus - pathogenicity
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - genetics
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - virology
Host-Pathogen Interactions
Humans
int
Interferons - therapeutic use
interleukin
Interleukins - genetics
Pharmacogenetics
Phenotype
Polymorphism
Polymorphism, Genetic
Ribavirin - therapeutic use
Topic Highlight
Treatment Outcome
virus
Interleukin 28B
Interferon
Hepatitis B virus
Pegylated interferon
Polymorphism
Online AccessGet full text

Cover

More Information
Summary:interleukin(iL)28B genetic polymorphism is significantly associated with the sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-α(PEG-iFN)plus ribavirin and with spontaneous hepatitis C virus clearance.However,a consensus on the relationship between iL28B genetic polymorphism and the favorable outcome of chronic hepatitis B virus infection defined by hepatitis B e antigen seroconversion,and/or hepatitis B surface antigen seroclearance in patients treated with interferon or PEG-iFN has not been reached.Several reports failed to show a positive association,while some studies demonstrated a positive association in certain subject settings.More prospective studies including large cohorts are needed to determine the possible association between iL28B genetic polymorphism and the outcome of interferon or PEG-iFN treatment for chronic hepatitis B.
Bibliography:Toru Takahashi;Division of Gastroenterology and Hepatology,Uonuma Hospital,Ojiyashi,Niigata 947-0028,Japan
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Telephone: +81-25-8832870 Fax: +81-25-8834789
Correspondence to: Toru Takahashi, MD, PhD, Director, Division of Gastroenterology and Hepatology, Uonuma Hospital, 4-1-38 Jonai, Ojiyashi, Niigata 947-0028, Japan. torutoru@uonumahosp.jp
Author contributions: Takahashi T solely contributed to this paper.
ISSN:1007-9327
2219-2840
2219-2840
DOI:10.3748/wjg.v20.i34.12026